Cryoport (CYRX) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue reached $45.5M, up 14–14.5% year-over-year, with strong double-digit growth in Life Sciences Services and Products, notably in BioLogistics Solutions and BioStorage/BioServices.

• Commercial Cell & Gene Therapy revenue increased 33% to $8.7M, supporting 18 commercial therapies and 728 clinical trials globally as of June 30, 2025.

• Strategic partnership with DHL Group completed, including the divestiture of CRYOPDP for $133M–$200M, enhancing global biologistics capabilities.

• Net income for Q2 2025 was $105.2M, primarily due to a $116.7M–$117.4M gain from the CRYOPDP sale.

• Gross margin improved to 47.0%, reflecting operational efficiencies and favorable product mix.

Financial highlights

• Life Sciences Services revenue grew 20.9%–21% year-over-year to $24.4M; Life Sciences Products revenue rose 7.8%–8% to $21.1M.

• BioStorage/BioServices revenue up 28% year-over-year; Commercial Cell & Gene Therapy revenue up 32.2%–33%.

• Adjusted EBITDA from continuing operations improved to -$0.9M from -$5.6M in the prior year.

• Cash, cash equivalents, and short-term investments totaled $426M as of June 30, 2025.

Outlook and guidance

• Full-year 2025 revenue guidance reaffirmed at $165M–$172M, reflecting 5%–10% year-over-year growth.

• Guidance incorporates a $2M revenue impact from a gene therapy client and excludes new approvals due to ramp-up time.

• No expectation for market expansion or recovery in China in 2025; ongoing macroeconomic, geopolitical, and sector-specific challenges anticipated.